Navigation Links
Ascendis Pharma Announces the Appointment of Thomas P. Soloway as Chief Financial Officer
Date:1/9/2014

COPENHAGEN, Denmark, Jan. 9, 2014 /PRNewswire/ -- Ascendis Pharma A/S announced today that Thomas P. Soloway has been appointed Chief Financial Officer.  Mr. Soloway joins the company after holding the positions of Chief Financial Officer and Chief Operating Officer at Transcept Pharmaceuticals, Inc.

"Tom's strong background in both the US capital markets and operating positions will be an important asset to Ascendis," stated Jan Moller Mikkelsen, Chief Executive Officer.  "Tom will play a key leadership role as we continue to execute on our strategic plan.  Tom joins our organization at a particularly exciting time. In addition to our large pharma partnerships in diabetes, pulmonary arterial hypertension and ophthalmology, we recently initiated a Phase 2 trial with our human growth hormone product in children, and launched a new initiative in the large and growing osteoarthritis market."

Mr. Soloway said, "What attracts me to Ascendis is its experienced leadership team, a strong pipeline of development stage programs, and a clinically proven prodrug technology platform that has been commercially validated by large pharma partnerships.  I am excited to join a company with a track record of strong execution and look forward to contributing to our continued growth."

Mr. Soloway joins Ascendis from Transcept Pharmaceuticals, Inc. where he was a co-founder of the company and served initially as Chief Financial Officer and later as Executive Vice President and Chief Operating Officer.  In these roles, Mr. Soloway led all investor relations activities and was a key member of the executive management team overseeing clinical development, regulatory affairs, pharmaceutical sciences, manufacturing and all financial activities.  Mr. Soloway led Transcept through its transition from a private to public company and raised more than $200 million for Transcept during his tenure.  Earlier in his career, Mr. Soloway was a Principal at Montreux Equity Partners, a life sciences focused venture capital firm. Mr. Soloway received a Bachelor of Science in Entrepreneurial Studies from the University of Southern California and a Masters of Business Administration from Georgetown University.

About Ascendis Pharma

Ascendis Pharma develops differentiated prodrug versions of high-value drugs. The company's proprietary TransCon technology is used to generate product candidates that are improved versions of existing drugs, yielding more effective, lower-risk therapeutics with new patent life.

Ascendis Pharma has a diversified and balanced high-value pipeline. Ascendis has strategic partnerships with Sanofi in diabetes, United Therapeutics in pulmonary arterial hypertension and an undisclosed market leader in the field of ophthalmology.

For more information, visit www.ascendispharma.com.  

Contact
Thomas P. Soloway
Chief Financial Officer, Ascendis Pharma A/S
Phone: 415.699.9924
Email:   ts@ascendispharma.com

 


'/>"/>
SOURCE Ascendis Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
2. Adamas Pharmaceuticals Earns $40 Million in Milestone Payments from Forest Laboratories for MDX-8704
3. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
4. Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
5. Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars
6. FPR Specialty Pharmacy Hires Slomski To Lead Sales And Marketing; Moves To Next Phase In Cleveland Clinic Trials
7. Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer
8. Upcoming Conferences, Share Price Updates, and Leadership Changes - Research Report on Lilly, Allergan, Waters, Novavax, and Supernus Pharmaceuticals
9. Auxilium Pharmaceuticals, Inc. To Present At The J.P. Morgan 32nd Annual Healthcare Conference
10. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
11. Sutro Biopharma to Collaborate With Memorial Sloan-Kettering Cancer Center to Produce Bispecific Antibodies for the Treatment of Neuroblastoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... GREENWICH, Connecticut , January 24, 2017 ... Gemeinschaftsprojekts mit dem Molecular Surgical Laboratory des Massachusetts General ... angekündigt. Dabei geht es um die Identifizierung und ... von innovativen Ansätzen, dass sie der Resistenz von Antibiotika ... ...
(Date:1/24/2017)... 23, 2017 Optoelectronic components have the ... The interaction of these components with light makes ... range of applications. These components are primarily used ... and healthcare among others. Growing application ... low power consumption, reliability, scalability, and performance is ...
(Date:1/24/2017)... , Jan. 23, 2017 INTRODUCTION ... way from conventional syringes with vials to prefilled ... These modern devices have become preferred devices for ... prefilled syringes has been rising strongly over the ... facilities are now adopting this format for delivering ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, parent company ... metrics into the product’s app. The data replicates and validates Co-Founder and ... just 30 seconds of using Buzzies, people experienced a 74 percent reduction in ...
(Date:1/23/2017)... ... 2017 , ... PKF O’Connor Davies , LLP, the nation’s 26th largest ... the Firm, will participate in the 40th Annual "Empire State Building Run Up" on ... 1,576 steps, a vertical distance equal to about a fifth of a mile, to ...
(Date:1/23/2017)... ... 2017 , ... Wooden and plastic balance boards have been around since at least the 1950s ... is the first and only balance board to use a patent-pending design featuring high-pressure ... the same time as well as skill-level adjustable for all ages and abilities. The ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... paper on Crystallization in Process Chemistry by Applying Simple PAT Tools . ... organic compounds to isolate and purify the desired product. Chemists now spend ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and ... Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality ...
Breaking Medicine News(10 mins):